Catalent (NYSE:CTLT) Downgraded by Deutsche Bank Aktiengesellschaft to “Hold”

Deutsche Bank Aktiengesellschaft cut shares of Catalent (NYSE:CTLT – Get Rating) from a buy rating to a hold rating in a report published on Monday, The Fly reports. The firm currently has $29.00 target price on the stock, down from their prior target price of $55.00.

CTLT has been the subject of several other research reports. Bank of America downgraded shares of Catalent from a neutral rating to an underperform rating and set a $28.00 price objective for the company. in a research report on Monday, May 8th. Robert W. Baird lowered shares of Catalent from an outperform rating to a neutral rating and cut their price objective for the stock from $82.00 to $53.00 in a report on Monday, April 17th. William Blair downgraded Catalent from an outperform rating to a market perform rating in a research note on Friday, April 14th. Barclays cut their price target on Catalent from $70.00 to $40.00 in a research note on Monday, April 17th. Finally, StockNews.com raised Catalent to a sell rating in a report on Saturday, April 15th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average price target of $74.80.

Catalent Price Performance

Shares of NYSE CTLT opened at $33.19 on Monday. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.91 and a quick ratio of 1.38. Catalent has a 1-year low of $31.45 and a 1-year high of $115.33. The company has a market capitalization of $5.98 billion, a price-to-earnings ratio of 14.69, a PEG ratio of 2.38 and a beta of 1.17. The business has a 50-day moving average of $55.92 and a 200-day moving average of $53.74.

Insiders Place Their Bets

In other Catalent news, SVP Mario Gargiulo sold 678 shares of the stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $33,805.08. Following the sale, the senior vice president now directly owns 5,676 shares of the company’s stock, valued at $283,005.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Mario Gargiulo sold 678 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $33,805.08. Following the completion of the transaction, the senior vice president now owns 5,676 shares in the company, valued at approximately $283,005.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Manja Boerman sold 1,446 shares of the stock in a transaction on Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $72,097.56. Following the completion of the sale, the insider now directly owns 14,414 shares in the company, valued at $718,682.04. The disclosure for this sale can be found here. 0.58% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CTLT. Davidson Kempner Capital Management LP acquired a new stake in shares of Catalent in the first quarter valued at approximately $12,156,000. Advisor Partners II LLC grew its holdings in Catalent by 19.5% in the 1st quarter. Advisor Partners II LLC now owns 7,127 shares of the company’s stock worth $468,000 after buying an additional 1,163 shares in the last quarter. Ensign Peak Advisors Inc increased its position in Catalent by 4.2% in the 1st quarter. Ensign Peak Advisors Inc now owns 54,510 shares of the company’s stock valued at $3,582,000 after acquiring an additional 2,200 shares during the period. Mirova bought a new stake in Catalent during the 1st quarter valued at $103,000. Finally, Ossiam boosted its position in Catalent by 243.3% during the 1st quarter. Ossiam now owns 5,767 shares of the company’s stock worth $379,000 after acquiring an additional 4,087 shares during the period. 99.38% of the stock is owned by institutional investors and hedge funds.

Catalent Company Profile

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.